Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...
Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...
Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.
Board member since March 2023 Nationality: British/American | Year of birth: 1964 A scientist by training, John D. Young has over 35 years of experience in the healthcare industry and brings a wealth ...
Transforming the treatment and healthcare system landscape using early interventions, pioneering treatments, and innovative partnerships to avoid preventable mortality from cardiovascular disease (CVD ...
Join our network of bright and curious minds What makes building a career here so rewarding? It’s being part of a community of smart, dedicated people. Professionals you can admire, learn from, and ...
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...
Novartis uses the open-source Drupal content management framework for many key websites, including our flagship global site Novartis.com, main country sites, portals for healthcare professionals, and ...
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of ...
2026年6月1日、スイス・バーゼル発 ― ノバルティスは本日、2026年米国臨床腫瘍学会（ASCO）年次総会において、「セムブリックス ® （一般名：アシミニブ塩酸塩 / 以下、セムブリックス ...
Lernen Sie die Kultur von Novartis kennen: Unbossed, Inspired, Curious.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results